Brief: Ipsen SA Says Cabometyx Approved In EU For Previously Treated Advanced Neuroendocrine Tumors
24/07/2025 19:25
July 24 (Reuters) - Ipsen SA IPN.PA: IPSEN SA: CABOMETYX APPROVED IN EU FOR PREVIOUSLY TREATED ADVANCED NEUROENDOCRINE TUMORS Source text: ID:nGNX51Jvlm Further company coverage: IPN.PA (((( Reuters.Briefs@thomsonreuters.com ;));))
Recent news on Ipsen SA
See all newsHealth Rounds: New blood test matches gold standard for liver disease diagnosis
Brief: Ipsen Late-Breaking Data Raises Ambitions In PBC
Brief: Charles River Laboratories International Virtual Control Group To Be Used In Glp Study For Ipsen
Pharming shares rise after preliminary Q3 revenue beat
France's Ipsen Q3 sales rise 28% driven by core portfolio